Evidence map›Paper›PMID 36965147›Full record

ArticleESC heart failure2023

Regional management of worsening heart failure: rationale and design of the CHAIN-HF registry.

Abdul Shakoor, Mireille E Emans, Marco W F van Gent, Anneke Hendrix, Nikola Faber, Tirza S Springeling, Liesbeth C de Vette, Olivier C Manintveld, Robert N Denham, Chajja van de Meerendonk and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Abdul ShakoorDepartment of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-7789-2022
Mireille E EmansDepartment of Cardiology, Ikazia Hospital, Rotterdam, The Netherlands.
Marco W F van GentDepartment of Cardiology, Albert Schweitzer Hospital, Rotterdam, The Netherlands.
Anneke HendrixDepartment of Cardiology, Franciscus & Vlietland Hospital, Rotterdam, The Netherlands.
Nikola FaberDepartment of Cardiology, Bravis Hospital, Bergen op Zoom/Roosendaal, The Netherlands.
Tirza S SpringelingDepartment of Cardiology, Rivas Zorggroep, Gorinchem, The Netherlands.
Liesbeth C de VetteDepartment of Cardiology, van Weel Bethesda Hospital, Dirksland, The Netherlands.
Olivier C ManintveldDepartment of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Robert N DenhamDepartment of Cardiology, Admiraal de Ruyter Hospital, Goes, The Netherlands.
Chajja van de MeerendonkDepartment of Cardiology, Maasstad Ziekenhuis, Rotterdam, The Netherlands.
Robert M A van der BoonDepartment of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Jasper J BrugtsDepartment of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Rijnmond Heart Failure Network
Erasmus MC · NLAdmiraal De Ruyter Ziekenhuis · NLAlbert Schweitzer Hospital · GABethesda Hospital · INBravis Ziekenhuis · NLFranciscus Vlietland · NLIkazia Ziekenhuis · NLMaasstad Ziekenhuis · NLTreant Zorggroep · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHeart failure (HF) is a progressive disease in which periods of clinical stability are interrupted by episodes of clinical deterioration known as worsening heart failure (WHF). Patients who develop WHF are at high risk of subsequent death, rehospitalization, and excessive healthcare costs. As such, WHF could be seen as a separate disease stage and precursor of advanced HF. Whether WHF has a substantial health, societal, and economic impact evidence regarding its multifactorial nature and the specific barriers in treatment, including advanced HF therapies, remains scarce. The CHAIN-HF registry aims to describe the incidence, characteristics, current treatment, and outcomes of WHF. Additionally, it will promote structured regional collaboration and educate on increasing awareness for WHF and describe the implementation of guideline directed medical therapy and utilization of advanced HF therapies in a collaborative network. METHODS AND

resultsThe CHAIN-HF registry is a prospective, observational, and multicentre study from the collaborating hospitals (Rijnmond HF Network) in the Rotterdam area. Unselected and consecutive patients (irrespective of ejection fraction) with a WHF event will be included. Comprehensive data including demographics, co-morbidities, treatment, and in-hospital and post-discharge outcomes will be collected. Notably, data on socio-economic status, treatment decisions, and referral for advanced HF therapies will be included.

conclusionsCHAIN-HF will be the first prospective, dedicated WHF registry in a collaborative network of hospitals that will provide robust real-world evidence on the incidence, characteristics, and outcomes of WHF. Moreover, it will provide information on of the value of regional collaboration to improve awareness and outcomes of WHF.

Indexed as

Heart FailureHospitalizationAcute DiseaseAftercareDisease ProgressionHumansPatient DischargeProspective StudiesRegistriesAdvanced heart failure therapiesHub-and-spoke modelMedical treatmentRegional collaborationWorsening heart failure

Identifiers

PMID36965147
PMCPMC10192238
OpenAlexW4360938502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.